Horizon Investment Services LLC Has $1.41 Million Holdings in Halozyme Therapeutics, Inc. $HALO

Horizon Investment Services LLC boosted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 87.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 27,062 shares of the biopharmaceutical company’s stock after acquiring an additional 12,596 shares during the period. Horizon Investment Services LLC’s holdings in Halozyme Therapeutics were worth $1,408,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the business. OneDigital Investment Advisors LLC lifted its position in shares of Halozyme Therapeutics by 1.7% during the 1st quarter. OneDigital Investment Advisors LLC now owns 10,176 shares of the biopharmaceutical company’s stock worth $649,000 after purchasing an additional 175 shares during the last quarter. Penserra Capital Management LLC bought a new position in Halozyme Therapeutics in the 1st quarter worth approximately $125,000. Envestnet Asset Management Inc. boosted its holdings in Halozyme Therapeutics by 0.4% in the 1st quarter. Envestnet Asset Management Inc. now owns 303,774 shares of the biopharmaceutical company’s stock valued at $19,384,000 after purchasing an additional 1,161 shares during the period. Nisa Investment Advisors LLC grew its position in Halozyme Therapeutics by 4.0% in the 1st quarter. Nisa Investment Advisors LLC now owns 5,611 shares of the biopharmaceutical company’s stock worth $358,000 after purchasing an additional 215 shares during the last quarter. Finally, State of Michigan Retirement System grew its position in Halozyme Therapeutics by 1.0% in the 1st quarter. State of Michigan Retirement System now owns 30,438 shares of the biopharmaceutical company’s stock worth $1,942,000 after purchasing an additional 300 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently weighed in on HALO shares. Leerink Partnrs upgraded shares of Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 14th. Citizens Jmp upped their price target on Halozyme Therapeutics from $91.00 to $92.00 and gave the company a “market outperform” rating in a report on Tuesday. The Goldman Sachs Group started coverage on Halozyme Therapeutics in a report on Thursday, July 10th. They set a “neutral” rating and a $55.00 price objective on the stock. HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, October 21st. Finally, Wall Street Zen lowered shares of Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 5th. Six investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, Halozyme Therapeutics currently has an average rating of “Hold” and a consensus target price of $75.00.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, CFO Nicole Labrosse sold 20,000 shares of the business’s stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $75.71, for a total value of $1,514,200.00. Following the completion of the transaction, the chief financial officer directly owned 24,306 shares of the company’s stock, valued at approximately $1,840,207.26. The trade was a 45.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Bernadette Connaughton sold 4,000 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $73.68, for a total transaction of $294,720.00. Following the sale, the director directly owned 46,952 shares in the company, valued at $3,459,423.36. This trade represents a 7.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 108,227 shares of company stock worth $7,779,595. 2.40% of the stock is currently owned by insiders.

Halozyme Therapeutics Trading Up 0.1%

Shares of Halozyme Therapeutics stock opened at $68.39 on Friday. Halozyme Therapeutics, Inc. has a 12-month low of $42.01 and a 12-month high of $79.50. The stock has a market capitalization of $8.00 billion, a P/E ratio of 15.65, a price-to-earnings-growth ratio of 0.35 and a beta of 1.18. The company has a 50-day simple moving average of $70.76 and a 200 day simple moving average of $62.75. The company has a quick ratio of 7.01, a current ratio of 8.36 and a debt-to-equity ratio of 4.54.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.63 by $0.09. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The firm had revenue of $354.26 million for the quarter, compared to analysts’ expectations of $339.18 million. During the same period in the prior year, the firm earned $1.27 earnings per share. The company’s quarterly revenue was up 22.1% compared to the same quarter last year. Research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.